Novo Nordisk To Appeal Decision On Norditropin

Law360, New York (September 8, 2004, 12:00 AM EDT) -- Danish drug maker Novo Nordisk has decided to appeal a court decision that rendered its patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct.

In a decision issued on August 3, Judge Susan Robinson of the U.S. District Court for the District of Delaware dealt a blow to the world’s largest insulin maker’s bid to block Israeli generics maker Teva Pharmaceuticals Industries Ltd. and Savient Pharmaceuticals Inc. from selling human growth hormone in the U.S.

The judge said a patent owned by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.